May 29, 2018
Amunix announces report by Bioverativ on unprecedented half-life obtained in patients treated with a novel, long-acting FVIII utilizing Amunix’s XTEN® technology
February 20, 2018
Amunix announces XTEN® and ProTIA technology licensing agreement with Celgene
February 13, 2018
Amunix CEO to deliver keynote address on ProTIA, Amunix’s novel immuno-oncology technology, at the Biologics & Biosimilars Congress Europe (March 2018)
XTEN® is a registered trademark of Amunix Operating Inc.